Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology  |  Pediatrics/Neonatology

Search Medical Condition
Please enter condition
Please choose location

Leukemia (Pediatric) Clinical Trials

A listing of Leukemia (Pediatric) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (240) clinical trials

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01190930?term=AALL0932&rank=1

Phase N/A

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01307579?term=Children%27s+Oncology+Group&cond=Prevent+Invasive+Fungal+Infection+in+Children+Undergoing+Chemotherapy+for+Acute+Myeloid+Leukemia+%28AML%29&rank=1

Phase N/A

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT00408005?term=AALL0434&rank=2

Phase N/A

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01142427?term=AALL08B1&rank=1

Phase N/A

Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults

1.0 GOALS AND OBJECTIVES (SCIENTIFIC AIMS) 1.1 Primary Aims 1.1.1 To evaluate the feasibility and toxicity of using bortezomib in combination with the ALL R3 re-induction regimen in pediatric patients with relapsed or refractory ALL or LL. 1.1.2 To determine the rate of complete response and negative minimal residual disease ...

Phase

Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)

This is a Phase 1 study with ADCT-301 to evaluate the safety, tolerability and pharmacokinetics of ADCT-301 in patients with Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL). ADCT-301 is a human monoclonal antibody attached via a cleavable linker to a pyrrolobenzodiazepine (PBD) warhead which, when internalized by antigen ...

Phase

A Study Evaluating KTE-C19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)

This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of KTE-C19, an autologous anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).

Phase

A Multi-Center Study Evaluating KTE-C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of KTE-C19, an autologous anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) in pediatric or adolescent subjects.

Phase